Cornell University, Ithaca, NY, USA.
Sinus and Nasal Institute of Florida, St Petersburg, FL, USA.
Ear Nose Throat J. 2024 Apr;103(4):255-257. doi: 10.1177/01455613211048984. Epub 2021 Oct 2.
The coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2. Rapid spread with rampant growth of cases and deaths brought forth an urgent need for novel therapies including vaccinations. The mRNA vaccines for COVID-19 disease have been implemented at an unprecedented scale in an effort to combat the unrelenting pandemic. Such a massive scale vaccination program is bound to coincide with adverse events related to treatment. We present a case of massive cervical lymphadenopathy in a 58-year-old male patient post-Moderna COVID-19 vaccination. Additional investigations did not identify malignancy and he was diagnosed with vaccine-related lymphadenopathy. Patient significantly improved with corticosteroid treatment within 2 days of admission. Lymphadenopathy is reported as the second most common local reaction to the Moderna vaccine. Promoting knowledge of this side effect, particularly in the setting widespread vaccination efforts, would allow for better management of cases, especially in relation to oncologic patients.
新型冠状病毒病（COVID-19）是由严重急性呼吸系统综合征冠状病毒 2 引起的全球大流行疾病。病例和死亡的快速传播呈猖獗之势，因此迫切需要包括疫苗接种在内的新型疗法。为了应对这场持续不断的大流行，mRNA 疫苗被前所未有地大规模用于 COVID-19 疾病的防治。如此大规模的疫苗接种计划必然会伴随着与治疗相关的不良事件。我们报告了一例 58 岁男性患者在接种 Moderna COVID-19 疫苗后出现巨大的颈部淋巴结病。进一步的检查并未发现恶性肿瘤，他被诊断为与疫苗相关的淋巴结病。患者在入院后 2 天内接受皮质类固醇治疗后显著改善。淋巴结病是 Moderna 疫苗最常见的第二大局部反应。提高对这种副作用的认识，特别是在广泛接种疫苗的背景下，将有助于更好地管理病例，特别是与肿瘤患者相关的病例。
